Therapeutic Targets Database
BIDD Pharmainformatics Databases


TTD Target ID: TTDS00282

Target Information
Type of targetSuccessful target    
DiseaseChronic tendon injury[1]
[ICD9: 577.0-577.1   ICD10: K85, K86.0K86.1]
Drug(s)AprotininApprovedPerioperative blood loss[4][5]
DermolastinPhase IIAtopic Dermatitis, Alpha 1 Antitrypsin Deficiency[6][7][8][9]
DermolastinHalted in Phase IChronic Obstructive Pulmonary Disease[6][7][8][9]
DermolastinHalted in Phase IEmphysema[6][7][8][9]
EC NumberEC
Related US Patent6,583,177
Target ValidationClick to Find Target Validation Information.    
1- (3-Amino-benzyl)-1H-indole-5-carboxamidine[11]
1- (3-Nitro-benzyl)-1H-indole-5-carboxamidine[11]
2- (2-Hydroxy-phenyl)-1H-indole-5-carboxamidine[12]
2- (2-Iodo-phenyl)-benzo[d][1,3]oxazin-4-one[13]
4- (3,4-Diethoxy-benzylamino)-benzamidine[14]
4- (4-Benzyloxy-3-methoxy-benzylamino)-benzamidine[14]
4- (5-Nitro-indol-1-ylmethyl)-benzamidine[11]
Benzamidrazone analogue[18]
Benzamidrazone analogue[18]
Benzamidrazone analogue[18]
Benzamidrazone analogue[18]
Benzamidrazone analogue[18]
Benzamidrazone analogue[18]
Benzamidrazone analogue[18]
P1 argininal derivative[26]
P1 argininal derivative[26]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
Peptide boronate[27]
macrocyclic tripeptide motif[33]
tert-butyloxy carbonyl-D-Phe-pro-Arg-H[34]
Cross References 3D Structure
Related Literature
On-Line Medical Dictionary
Ref 1Reducing Extracellular pH Sensitizes the Acinar Cell to Secretagogue-Induced Pancreatitis Responses in Rats. Gastroenterology. 2009 May 18. [Epub ahead of print] To Reference
Ref 2Acute pancreatitis: animal models and recent advances in basic research. Pancreas. 2007 Jan;34(1):1-14. To Reference
Ref 3Enteropeptidase, a type II transmembrane serine protease. Front Biosci (Elite Ed). 2009 Jun 1;1:242-9. To Reference
Ref 4Identification and expression of the cDNA-encoding human mesotrypsin(ogen), an isoform of trypsin with inhibitor resistance. J Biol Chem. 1997 Apr 18;272(16):10573-8. To Reference
Ref 5Aprotinin decreases exposure to allogeneic blood during primary unilateral total hip replacement. J Bone Joint Surg Am. 2000 May;82(5):675-84. To Reference
Ref 6Arriva-ProMetic recombinant alpha 1-antitrypsin (rAAT) moves into the clinic for dermatology applications. ProMetic Life Sciences. 2009 To Reference
Ref 7rAAt (inhaled) Arriva/Hyland Immuno. Curr Opin Mol Ther. 2006 Feb;8(1):76-82. To Reference
Ref 8Optimization of the bioprocessing conditions for scale-up of transient production of a heterologous protein in plants using a chemically inducible viral amplicon expression system. Biotechnol Prog. 2009 May-Jun;25(3):722-34. To Reference
Ref 9Bioreactor strategies for improving production yield and functionality of a recombinant human protein in transgenic tobacco cell cultures. Biotechnol Bioeng. 2009 Feb 1;102(2):508-20. To Reference
Ref 10Bioorg Med Chem Lett. 2001 Jul 9;11(13):1691-4.Inhibition of serine proteases: activity of 1,3-diazetidine-2,4-diones. To Reference
Ref 11J Med Chem. 1983 Feb;26(2):294-8.Aromatic amidines: comparison of their ability to block respiratory syncytial virus induced cell fusion and to inhibit plasmin, urokinase, thrombin, and trypsin. To Reference
Ref 12J Med Chem. 2001 Aug 16;44(17):2753-71.Development of serine protease inhibitors displaying a multicentered short (<2.3 A) hydrogen bond binding mode: inhibitors of urokinase-type plasminogen activator and factor Xa. To Reference
Ref 13J Med Chem. 1998 Mar 26;41(7):1060-7.2-amino-4H-3,1-benzoxazin-4-ones as inhibitors of C1r serine protease. To Reference
Ref 14Bioorg Med Chem Lett. 2005 Feb 1;15(3):817-22.Design of selective phenylglycine amide tissue factor/factor VIIa inhibitors. To Reference
Ref 15Bioorg Med Chem Lett. 2005 Jan 3;15(1):93-8.Naphthamidine urokinase plasminogen activator inhibitors with improved pharmacokinetic properties. To Reference
Ref 16Bioorg. Med. Chem. Lett. 7(17):2205-2210 (1997) To Reference
Ref 17Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. To Reference
Ref 18Bioorg Med Chem Lett. 1999 Sep 6;9(17):2483-6.Fluorobenzamidrazone thrombin inhibitors: influence of fluorine on enhancing oral absorption. To Reference
Ref 19Bioorg Med Chem Lett. 2002 Apr 22;12(8):1203-8.Non-covalent thrombin inhibitors featuring P(3)-heterocycles with P(1)-monocyclic arginine surrogates. To Reference
Ref 20Bioorg Med Chem Lett. 1998 Nov 3;8(21):2955-60.5,5-trans lactone-containing inhibitors of serine proteases: identification of a novel, acylating thrombin inhibitor. To Reference
Ref 21J Med Chem. 2009 Sep 24;52(18):5732-47.Grassystatins A-C from marine cyanobacteria, potent cathepsin E inhibitors that reduce antigen presentation. To Reference
Ref 22Bioorg Med Chem Lett. 1998 Dec 15;8(24):3603-8.Novel acylguanidine containing thrombin inhibitors with reduced basicity at the P1 moiety. To Reference
Ref 23Bioorg. Med. Chem. Lett. 7(1):67-72 (1997) To Reference
Ref 24Bioorg Med Chem Lett. 2003 Jan 20;13(2):161-4.Small, low nanomolar, noncovalent thrombin inhibitors lacking a group to fill the 'distal binding pocket'. To Reference
Ref 25Bioorg Med Chem Lett. 2006 May 15;16(10):2641-7. Epub 2006 Mar 6.Orally active thrombin inhibitors. Part 1: optimization of the P1-moiety. To Reference
Ref 26Bioorg Med Chem Lett. 2002 Mar 11;12(5):743-8.Novel, potent non-covalent thrombin inhibitors incorporating p(3)-lactam scaffolds. To Reference
Ref 27J Med Chem. 1995 Apr 28;38(9):1511-22.Characterization of a class of peptide boronates with neutral P1 side chains as highly selective inhibitors of thrombin. To Reference
Ref 28J Med Chem. 2000 Aug 10;43(16):3033-44.GRID/CPCA: a new computational tool to design selective ligands. To Reference
Ref 29J Med Chem. 2005 Mar 24;48(6):1984-2008.In-depth study of tripeptide-based alpha-ketoheterocycles as inhibitors of thrombin. Effective utilization of the S1' subsite and its implications to structure-based drug design. To Reference
Ref 30J Med Chem. 2004 Feb 12;47(4):769-87.Inhibitors of serine proteases as potential therapeutic agents: the road from thrombin to tryptase to cathepsin G. To Reference
Ref 31Bioorg Med Chem Lett. 2003 Feb 10;13(3):561-6.Design, synthesis and structure-activity relationships of benzoxazinone-based factor Xa inhibitors. To Reference
Ref 32Bioorg Med Chem Lett. 1998 Aug 18;8(16):2235-40.Design, synthesis, and biological activity of novel purine and bicyclic pyrimidine factor Xa inhibitors. To Reference
Ref 33Bioorg. Med. Chem. Lett. 6(24):2947-2952 (1996) To Reference
Ref 34J Med Chem. 1995 Oct 27;38(22):4446-53.Structure-activity study of tripeptide thrombin inhibitors using alpha-alkyl amino acids and other conformationally constrained amino acid substitutions. To Reference


Welcome to sign our Guestbook.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhu.

Dr. Chen Yuzong
Deputy Director of Center for Computational Science and Engineering
Professor in Department of Pharmacy
National University of Singapore, Singapore

All rights reserved.

Computer-aided Drug Design
about BIDD |  databases |  software |  teaching |  research |  links


Department of Computational Science | National University of Singapore | Blk S17, 3 Science Drive 2, Singapore 117543